

Quintiles most preferred CRO for phase II/III trials

22 May 2013 | News | By BioSpectrum Bureau

Quintiles most preferred CRO for Phase II/III trials



A recent report has indicated that Quintiles best differentiates itself on service quality in phase II/III clinical research. The Industry Standard Research's (ISR) 2013 CRO Quality Benchmarking Report - phase II/III, asked 157 pharmaceutical and biotechnology professionals, who rated Quintiles as the leader among large CROs for customer loyalty, defined by overall satisfaction, willingness to recommend and likelihood to use Quintiles again.

"We are deeply committed to helping our customers increase their probability of success at every stage of the product lifecycle," said Ms Paula Brown Stafford, president, clinical development at Quintiles. "We are delighted to see that our leadership and commitment to both quality and customer satisfaction are recognized by the industry."

According to the report, Quintiles is the best phase II/III clinical research service provider at differentiation based on service quality; Quintiles leads large CROs in customer loyalty and is the most cited industry leader. It also exceeds expectations for global reach, breadth of services, local regulatory knowledge, commercial market knowledge and the ability to consistently meet "First Patient In" timelines.

Quintiles said that they are committed to transforming drug development through its data and proprietary knowledge engine, Quintiles Infosario, an innovative solution that seamlessly integrates data, Quintiles' systems, processes and therapeutic expertise to help customers make faster, more informed decisions. This recognition comes on the heels of Quintiles' award for Best CRO in Vaccine Industry Excellence presented in April 2013 at the World Vaccine Congress.